Treatment of diabetes in elderly of 65 years. Review and utility of glp-1 in this group of patients
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication are distributed under the Creative Commons Attribution-NonCommercial-Non Derivatives 4.0 International license (CC BY-NC-ND 4.0). The rights of the works published in this journal are the property of the author and they are free to distribute and disseminate them, as long as the source is correctly cited, no derivative works are generated and these acts do not have commercial purposes.
Main Article Content
Abstract
The prevalence of overweight and obesity has increased very significantly in recent decades and is a major public health problem in Spain and in most developed countries. Overweight and obesity increase the risk of many other diseases such as cardiovascular disease, insulin resistance, type 2 diabetes, hypertension, dyslipidemia and certain types of cancers. In this context, the increase in life expectancy in our environment, determines that in nursing homes prevalence of diabetes has increased from 16 to 23 percent in the period 1996-2004. In addition there are to take into account that older adults with diabetes suffer from excess morbidity and mortality compared with those without diabetes, which together with its basic characteristics, complicating their management. It is often found in these patients polypharmacy, functional disabilities, as well as geriatric syndromes common as cognitive impairment and risk of falls. Recently it has been marketed lixisenatide (LIX). It is a GLP-1 short-acting. We conducted a study in which we aim to evaluate the effect on glycemic control and other metabolic variables by adding lixisenatide (LIX) a cohort of patients older than 65 years treated with combination therapy of oral agents and basal insulin (BOT).
References
Abbatecola, A.M., y Paolisso, G. (2009). Diabetes care targets in older persons. Diabetes Research
and Clinical Practice, 86(Suppl 1), 35-40.
Adler, G.K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., y Freeman,R. (2009). Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes, 58(2), 360-366.
Ahrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., y Bailey, C. (2014). Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 16(9), 861-868.
American Diabetes Association. (2016). Standards of medical care in diabetes 2016. Diabetes Care, 39(Suppl 1), S1-S2.
Bethel, M.A., Sloan, F.A., Belsky, D., y Feinglos, M.N. (2007). Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Archives of Internal Medicine, 167(9), 921-927.
Charbonnel, B., Bertolini, M., Tinahones, F.J., Puig-Domingo, M., y Davies, M. (2014). Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. Journal of Diabetes and Its Complications, 28(6), 880-886.
Cowie, C.C., Rust, K.F., Ford, E.S., Eberhardt, M.S., Byrd-Holt, D.D., Li, C., … Geiss L.S. (2009). Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care, 32(2), 287-294.
Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393-403.
Distiller, L., y Ruus, P. (2008). Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist
AVE0010 in type 2 diabetes patients. Diabetes, 57(Suppl. 1), 154-155.
Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C. Jr., Bigger, J.T., Buse, J.B., … Friedewald, W.T. Action to Control Cardiovascular Risk in Diabetes Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 358(24), 2545-2559.
Kapitza, C., Forst T., Coester, H., Poitiers, F., Ruus, P., y Hincelin-Mery, A. (2013). Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes, Obesity and Metabolism, 15(7), 642-649.
Kirkman, M.S., Briscoe, V.J., Clark, N., … Swift, C.S. (2012). Consensus Development Conference on Diabetes and Older Adults. Diabetes in older adults: a consensus report. Journal of the American Geriatrics Society, 60(12), 2342-2356.
Kirkman, M.S., Briscoe, V.J., Clark, N., Florez, H., Haas, L.B., Halter, J.B., … Swift, C.S. (2012). Diabetes in older adults. Diabetes Care, 35(12), 2650-2664.
Ligthelm, R.J., Kaiser, M., Vora, J., y Yale, J.F. (2012). Insulin use in elderly adults: risk of hypoglycemia and strategies for care. Journal of the American Geriatrics Society, 60(8), 1564-1570.
Lorenz, M., Pfeiffer, C., Steinstraessner, A., Becker, R., Ruetten, H., Ruus, P., y Horowitz, M. (2013). Effects of lixisenatide once daily on gastric emptying in type 2 diabetes –relationship to postprandial glycaemia. Regulatory Peptides, 185, 1-8.
Meier, J.J., Yabe, D., Wang, E., Lin, J., Rosenstock, J. y Ahrén, B. (2013). Efficacy of lixisenatide
in patients with different levels of beta cell function as assessed by C-peptide/glucose ratio. Diabetologia, 56(Suppl1), S1-S566.
Miller, C.K., Edwards, L., Kissling, G., y Sanville, L. (2002). Nutrition education improves metabolic outcomes among older adults with diabetes mellitus: results from a randomized controlled trial. Preventive Medicine, 34(2), 252-259.
Mooradian, A.D., Perryman, K., Fitten, J., Kavonian, G.D., y Morley, J.E. (1988). Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies. Archives of Internal Medicine, 148(11), 2369-2372.
Nauck, M. (2013). A critical analysis of the clinical use of incretin-based therapies: the benefits by
far outweigh the potential risks. Diabetes Care, 36(7), 2126-2132.
Sinclair, A.J., Paolisso, G., Castro, M., Bourdel-Marchasson, I., Gadsby, R., y Rodríguez, L. (2011). European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes and Metabolism, 37(Suppl 3),27-38.
Whitmer, R.A., Karter, A.J., Yaffe, K., Quesenberry, C.P., y Selby, J.V. (2009). Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA, 301(15), 1565-1572.
Zhang, X., Decker, F.H., Luo, H., Geiss, L.S., Pearson, W.S., … Albright, A. (2010). Trends in the
prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995-2004. Journal of the American Geriatrics Society, 58(4), 724-730.